Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 in Chinese Patients With Moderate-to-Severe Plaque Psoriasis

NCT03364309 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03364309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03364309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
April 26, 2018
Completion date
June 4, 2020
Enrollment
438 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis